贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展

doi:10.3969/j.issn.1000-6621.2020.08.019

摘要/Abstract

摘要：

近年来,非结核分枝杆菌(non-tuberculous mycobacteria, NTM)引起的感染呈逐渐上升趋势,严重威胁人类健康。NTM致病的菌种繁多,不同菌种NTM对药品的敏感性各异,使其治疗存在较大困难。因此,寻找NTM病治疗效果较佳的药品非常有必要。NTM种属分布常具有地域特点,在多数地区鸟-胞内分枝杆菌复合群、脓肿分枝杆菌和堪萨斯分枝杆菌为较常见的致病菌种。贝达喹啉(bedaquiline, Bdq)、氯法齐明(clofazimine,Cfz)及德拉马尼(delamanid,Dlm)因对治疗NTM病体现出了良好的治疗潜力而受到泛关注。为了提高对抗NTM药品敏感性及耐药机制的认识,作者就Bdq、Cfz和Dlm对以上常见致病性NTM的体外抑菌活性及耐药相关机制进行综述。

关键词: 分枝杆菌, 非典型性, 贝达喹啉, 氯法齐明, 德拉马尼, 体外研究, 微生物敏感性试验, 药理作用分子作用机制, 综述文献(主题)

Abstract:

Recently, the infection of non-tuberculous mycobacteria (NTM) has increased rapidly and threatened human health. NTM differentiate into many species. Species diversity makes treatment of NTM extremely difficult. Thus,it is very important to find new and effective drugs. Bedaquiline, clofazimine and delamanid showed effectiveness in treating NTM. In order to improve the understanding of drug susceptibility and drug resistance mechanism of NTM, in vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic are described.

Key words: Mycobacteria, atypical, Bedaquiline, Clofazimine, Delamanid, In vitro, Microbial sensitivity tests, Molecular mechanisms of pharmacological action, Review literature as topic

孙晴, 黄海荣, 王桂荣. 贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展[J]. 中国防痨杂志, 2020, 42(8): 880-884. doi: 10.3969/j.issn.1000-6621.2020.08.019

SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. doi: 10.3969/j.issn.1000-6621.2020.08.019

参考文献 44

[1]	Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis, 2014,18(11):1370-1377. doi: 10.5588/ijtld.14.0120. doi: 10.5588/ijtld.14.0120 URL pmid: 25299873
[2]	Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis, 2016,45:123-134. doi: 10.1016/j.ijid.2016.03.006. URL pmid: 26976549
[3]	Singh P, Kumari R, Lal R. Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis. Indian J Microbiol, 2017,57(4):371-377. doi: 10.1007/s12088-017-0674-0. URL pmid: 29151636
[4]	Patel RV, Riyaz SD, Park SW. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis. Curr Top Med Chem, 2014,14(16):1866-1874. doi: 10.2174/156802661466614092 9114822. doi: 10.2174/1568026614666140929114822 URL pmid: 25262806
[5]	Yu X, Gao X, Li C, et al. In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother, 2019,63(8):e00031-19. doi: 10.1128/AAC.00031-19. doi: 10.1128/AAC.00031-19 URL pmid: 31138571
[6]	Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017,61(10):e00900-17. doi: 10.1128/AAC.00900-17. URL pmid: 28739779
[7]	Kim DH, Jhun BW, Moon SM, et al. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother, 2019,63(8):e00665-19. doi: 10.1128/AAC.00665-19. doi: 10.1128/AAC.00665-19 URL pmid: 31182533
[8]	DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii Infection: Beyond 2018. Front Microbiol, 2018,9:2271. doi: 10.3389/fmicb.2018.02271. doi: 10.3389/fmicb.2018.02271 URL pmid: 30319580
[9]	Brown-Elliott BA, Philley JV, Griffith DE, et al. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex. Antimicrob Agents Chemother, 2017,61(2):e01798-16. doi: 10.1128/AAC.01798-16. doi: 10.1128/AAC.01798-16 URL pmid: 27872065
[10]	Li B, Ye M, Guo Q, et al. Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus. Antimicrob Agents Chemother, 2018,62(7):e00175-18. doi: 10.1128/AAC.00175-18. doi: 10.1128/AAC.00175-18 URL pmid: 29712658
[11]	Dupont C, Viljoen A, Thomas S, et al. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and is Effective in Infected Zebrafish. Antimicrob Agents Chemother, 2017,61(11):e01225-17. doi: 10.1128/AAC.01225-17. doi: 10.1128/AAC.01225-17 URL pmid: 28807917
[12]	Huh HJ, Kim SY, Jhun BW, et al. Recent advances in mole-cular diagnostics and understanding mechanisms of drug resis-tance in nontuberculous mycobacterial diseases. Infect Genet Evol, 2019,72:169-182. doi: 10.1016/j.meegid.2018.10.003. doi: 10.1016/j.meegid.2018.10.003 URL pmid: 30315892
[13]	Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307(5707):223-227. doi: 10.1126/science.1106753. doi: 10.1126/science.1106753 URL pmid: 15591164
[14]	Aguilar-Ayala DA, Cnockaert M, André E, et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol, 2017,66(8):1140-1143. doi: 10.1099/jmm.0.000537. doi: 10.1099/jmm.0.000537 URL pmid: 28749330
[15]	Radhakrishnan A, Kumar N, Wright CC, et al. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. J Biol Chem, 2014,289(23):16526-16540. doi: 10.1074/jbc.M113.538959. doi: 10.1074/jbc.M113.538959 URL pmid: 24737322
[16]	Alexander DC, Vasireddy R, Vasireddy S, et al. Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. J Clin Microbiol, 2017,55(2):574-584. doi: 10.1128/JCM.02087-16. doi: 10.1128/JCM.02087-16 URL pmid: 27927925
[17]	Richard M, Gutiérrez AV, Viljoen A, et al. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother, 2018,63(1):e01316-18. doi: 10.1128/AAC.01316-18. doi: 10.1128/AAC.01316-18 URL pmid: 30323043
[18]	Mirnejad R, Asadi A, Khoshnood S, et al. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother, 2018,105:1353-1359. doi: 10.1016/j.biopha.2018.06.023. doi: 10.1016/j.biopha.2018.06.023 URL pmid: 30021373
[19]	Luo J, Yu X, Jiang G, et al. In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother, 2018,62(7):e00072-18. doi: 10.1128/AAC.00072-18. doi: 10.1128/AAC.00072-18 URL pmid: 29760127
[20]	Li G, Pang H, Guo Q, et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents, 2017,49(3):364-374. doi: 10.1016/j.ijantimicag.2016.10.024. doi: 10.1016/j.ijantimicag.2016.10.024 URL pmid: 28131606
[21]	van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents, 2010,35(2):169-173. doi: 10.1016/j.ijantimicag.2009.09.023. doi: 10.1016/j.ijantimicag.2009.09.023 URL pmid: 20006470
[22]	Shen Y, Wang X, Jin J, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int, 2018,2018:4902941. doi: 10.1155/2018/4902941. doi: 10.1155/2018/4902941 URL pmid: 30687747
[23]	Huang CC, Wu MF, Chen HC, et al. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. J Microbiol Immunol Infect, 2018,51(5):636-643. doi: 10.1016/j.jmii.2017.05.001. doi: 10.1016/j.jmii.2017.05.001 URL pmid: 28705770
[24]	Shen GH, Wu BD, Hu ST, et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents, 2010,35(4):400-404. doi: 10.1016/j.ijantimicag.2009.12.008. doi: 10.1016/j.ijantimicag.2009.12.008 URL pmid: 20138481
[25]	Ismail N, Peters RPH, Ismail NA, et al. Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance. Antimicrob Agents Chemother, 2019,63(3):e02141-18. doi: 10.1128/AAC.02141-18. doi: 10.1128/AAC.02141-18 URL pmid: 30642938
[26]	Chen Y, Chen J, Zhang S, et al. Novel Mutations Associated with Clofazimine Resistance in Mycobacterium abscessus. Antimicrob Agents Chemother, 2018,62(7):e00544-18. doi: 10.1128/AAC.00544-18. doi: 10.1128/AAC.00544-18 URL pmid: 29712660
[27]	Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs, 2015,75(1):91-100. doi: 10.1007/s40265-014-0331-4. doi: 10.1007/s40265-014-0331-4 URL pmid: 25404020
[28]	Bashiri G, Rehan AM, Greenwood DR, et al. Metabolic engi-neering of cofactor F420 production in Mycobacterium smegmatis. PLoS One, 2010,5(12):e15803. doi: 10.1371/journal.pone.0015803. doi: 10.1371/journal.pone.0015803 URL pmid: 21209917
[29]	Fujiwara M, Kawasaki M, Hariguchi N, et al. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb), 2018,108:186-194. doi: 10.1016/j.tube.2017.12.006.
[30]	Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemo-ther, 2018,62(11):e01503-18. doi: 10.1128/AAC.01503-18.
[31]	Cho EH, Huh HJ, Song DJ, et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. J Infect Chemother, 2018,24(4):315-318. doi: 10.1016/j.jiac.2017.10.022. doi: 10.1016/j.jiac.2017.10.022 URL pmid: 29223615
[32]	Litvinov V, Makarova M, Galkina K, et al. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. PLoS One, 2018,13(9):e0203108. doi: 10.1371/journal.pone.0203108. doi: 10.1371/journal.pone.0203108 URL pmid: 30222736
[33]	Heidarieh P, Mirsaeidi M, Hashemzadeh M, et al. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Microb Drug Resist, 2016,22(2):172-178. doi: 10.1089/mdr.2015.0134. doi: 10.1089/mdr.2015.0134 URL pmid: 26468990
[34]	Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007,175(4):367-416. doi: 10.1164/rccm.200604-571ST. doi: 10.1164/rccm.200604-571ST URL pmid: 17277290
[35]	van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol, 2014,9(9):1095-1110. doi: 10.2217/fmb.14.60. doi: 10.2217/fmb.14.60 URL pmid: 25340838
[36]	Jarand J, Davis JP, Cowie RL, et al. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. Chest, 2016,149(5):1285-1293. doi: 10.1378/chest.15-0543. doi: 10.1378/chest.15-0543 URL pmid: 26513209
[37]	Nie W, Duan H, Huang H, et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. Biomed Res Int, 2015,2015:506598. doi: 10.1155/2015/506598. doi: 10.1155/2015/506598 URL pmid: 26146620
[38]	Ananta P, Kham-Ngam I, Chetchotisakd P, et al. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand. PLoS One, 2018,13(11):e0208053. doi: 10.1371/journal.pone.0208053 doi: 10.1371/journal.pone.0208053 URL pmid: 30496270
[39]	Lavollay M, Dubée V, Heym B, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect, 2014,20(5):O297-O300. doi: 10.1111/1469-0691.12405. doi: 10.1111/1469-0691.12405 URL pmid: 24112243
[40]	Cho EH, Huh HJ, Song DJ, et al. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagn Microbiol Infect Dis, 2019,93(2):107-111. doi: 10.1016/j.diagmicrobio.2018.08.008. doi: 10.1016/j.diagmicrobio.2018.08.008 URL pmid: 30236529
[41]	Zhang Z, Lu J, Song Y, et al. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis, 2018,90(1):31-34. doi: 10.1016/j.diagmicrobio.2017.09.013. doi: 10.1016/j.diagmicrobio.2017.09.013 URL pmid: 29089153
[42]	Hatakeyama S, Ohama Y, Okazaki M, et al. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis, 2017,17(1):197. doi: 10.1186/s12879-017-2298-8. doi: 10.1186/s12879-017-2298-8 URL pmid: 28270102
[43]	Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Antimicrob Agents Chemother, 2015,60(2):1097-1105. doi: 10.1128/AAC.02615-15. doi: 10.1128/AAC.02615-15 URL pmid: 26643335
[44]	Yang B, Jhun BW, Moon SM, et al. Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother, 2017,61(6):e02052-16. doi: 10.1128/AAC.02052-16. doi: 10.1128/AAC.02052-16 URL pmid: 28348153